Development of mTORC1 specific agents for evaluation of HER2 targeted therapy using PET

被引：0
|
作者：
Wichmann, Christian W. [1 ,2 ]
Ackermann, Uwe [2 ,3 ]
Parslow, Adam C. [3 ,4 ]
Rigopoulos, Angela [3 ]
Scott, Andrew M. [3 ,4 ]
White, Jonathan M. [1 ]
机构：
[1] Univ Melbourne, Sch Chem, Bio21 Inst, Parkville, Vic, Australia
[2] Austin Hlth, Ctr PET, Heidelberg, Vic, Australia
[3] Olivia Newton John Canc Res Inst, Tumour Targeting Lab, Heidelberg, Vic, Australia
[4] La Trobe Univ, Sch Canc Med, Bundoora, Vic, Australia
来源：
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS | 2017年 / 60卷
基金：
澳大利亚国家健康与医学研究理事会;
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学];
学科分类号：
071010 ; 081704 ;
摘要：
P 333
引用
收藏
页码：S506 / S506
页数：1
相关论文
共 50 条
  • [1] DEVELOPMENT OF MTORC1 SPECIFIC AGENTS FOR EVALUATION OF HER2 TARGETED THERAPY USING PET
    Wichmann, C.
    Parslow, A.
    Ackermann, U.
    Rigopoulos, A.
    Scott, A. M.
    White, J.
    INTERNAL MEDICINE JOURNAL, 2018, 48 : 13 - 13
  • [2] Development of small-molecule mTORC1 radiotracers for evaluation of targeted therapy resistance using PET
    Parslow, Adam C.
    Wichmann, Christian W.
    Rigopoulos, Angela
    Ackermann, Uwe
    White, Jonathan M.
    Scott, Andrew M.
    CANCER RESEARCH, 2018, 78 (13)
  • [3] Development of HER2 targeted therapy
    Tamura, Kenji
    CANCER SCIENCE, 2021, 112 : 158 - 158
  • [4] Dual MTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
    Garcia-Garcia, C.
    Ibrahim, Y. H.
    Serra, V.
    Calvo, M. T.
    Aura, C.
    Perez, J.
    Rommel, C.
    Tabernero, J.
    Baselga, J.
    Scaltriti, M.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S192 - S192
  • [5] Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
    Garcia-Garcia, Celina
    Ibrahim, Yasir H.
    Serra, Violeta
    Teresa Calvo, Maria
    Guzman, Marta
    Grueso, Judit
    Aura, Claudia
    Perez, Jose
    Jessen, Katti
    Liu, Yi
    Rommel, Christian
    Tabernero, Josep
    Baselga, Jose
    Scaltriti, Maurizio
    CLINICAL CANCER RESEARCH, 2012, 18 (09) : 2603 - 2612
  • [6] Her2 a paradigm for targeted therapy
    Marijon, Helene
    Andre, Fabrice
    BULLETIN DU CANCER, 2011, 98 (09) : 1011 - 1017
  • [7] mTORC1 Activity Contributes to the Mcl-1 Dependence of HER2 Amplified Breast Cancer Cells
    Campone, M.
    Noel, B.
    Gouraud, W.
    Jezequel, P.
    Barille-Nion, S.
    Juin, P.
    CANCER RESEARCH, 2009, 69 (24) : 644S - 644S
  • [8] Hyperactivation of mTORC1 drives acquired resistance to the pan HER tyrosine kinase inhibitor neratinib in HER2 mutant cancers
    Sudhan, Dhivya R.
    Hanker, Ariella B.
    Guerrero-Zotano, Angel
    Formisano, Luigi
    Guo, Yan
    Liu, Qi
    Avogadri-Connors, Francesca
    Cutler, Richard E.
    Lalani, Alshad S.
    Bryce, Richard
    Auerbach, Alan
    Arteaga, Carlos L.
    CANCER RESEARCH, 2018, 78 (13)
  • [9] The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways
    Dena A. Jerjees
    Ola H. Negm
    M. Layth Alabdullah
    Sameer Mirza
    Methaq Alkaabi
    Mohamed R. Hameed
    Rezvan Abduljabbar
    Abir Muftah
    Chris C. Nolan
    Andrew R. Green
    Patrick J. Tighe
    Vimla Band
    Ian O. Ellis
    Emad A. Rakha
    Breast Cancer Research and Treatment, 2015, 150 : 91 - 103
  • [10] Discovery and development of small molecule inhibitors of mTORC1 and mTORC2 as potential anti -cancer agents
    Shokat, Kevan
    CANCER RESEARCH, 2009, 69
12345